BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Business

  BioAtla Presents CAB-CTLA-4 And CAB-EpCAM-ADC Data At The American Association For Cancer Research Annual Meeting

  Oral presentation highlights CAB-CTLA-4 pre-clinical data demonstrating expected efficacy and reduced immune side effects and toxicities as monotherapy or in combination with PD-1 inhibitors

  February 27, 2019

   · 

  5 min read
• Drug Development

  ALX Oncology to Present Preclinical Data on SIRPα Antibody Program at Upcoming Conferences

  ALX Oncology announced that preclinical data for its SIRPα antibody research program will be presented at the 2019 Keystone Symposia Conference, Cancer Immunotherapy in Whistler, British Columbia and the American Association for Cancer Research Annual Meeting 2019 in Atlanta, Georgia.

  February 27, 2019

   · 

  3 min read
• Drug Development

  Tetraphase Pharmaceuticals to Present Data on Preclinical Activity of TP-2846 in Acute Myeloid Leukemia

  Data to be Presented at the 2019 American Association for Cancer Research Annual Meeting

  February 27, 2019

   · 

  4 min read
• Policy

  Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)

  Bayer announced the completion of the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational drug darolutamide.

  February 27, 2019

   · 

  6 min read
• Deals

  Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2018

  Nordic Nanovector ASA announces its results for the fourth quarter and full year 2018.

  February 27, 2019

   · 

  7 min read
• Business

  Harvard and University of North Carolina researchers awarded grants funded by Alzheimer’s Germ Quest to investigate microbes in Alzheimer’s disease, announces Dr. Leslie Norins, CEO

  Research grant funds made available by Alzheimer’s Germ Quest, Inc., have been awarded to two researchers, one at Harvard and the other at University of North Carolina, to investigate roles of microbes in Alzheimer’s disease, announces Leslie Norins, MD, PhD, company CEO.

  February 27, 2019

   · 

  1 min read
• Business

  United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results

  United Therapeutics Corporation announced its financial results for the fourth quarter and year ended December 31, 2018.

  February 27, 2019

   · 

  19 min read
• Business

  LivaNova Reports Fourth Quarter and Full-Year 2018 Results

  LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter and full-year ended December 31, 2018.

  February 27, 2019

   · 

  37 min read
• Business

  Ionis Exceeds 2018 Financial Guidance

  Ionis Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year 2018 and reviewed highlights of its successful year.

  February 27, 2019

   · 

  20 min read
• Policy

  DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter

  DURECT Corporation announced it has completed a comprehensive review of its POSIMIR® program and plans to submit a full response to the Complete Response Letter it previously received from U.S. Food and Drug Administration.

  February 27, 2019

   · 

  7 min read